MAPT and Alzheimer disease: Together with the recognition that AD can be quite heterogeneous among populational cohorts and have multiple subtypes [7,8], there remains an urgent need to develop additional and complementary therapeutic options, including tau-targeting therapies that address the other major amyloidogenic components found in AD brains.